After finishing at $7.04 in the prior trading day, Travere Therapeutics Inc (NASDAQ: TVTX) closed at $6.96, down -1.14%. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 534602 shares were traded. TVTX stock price reached its highest trading level at $7.14 during the session, while it also had its lowest trading level at $6.93.
Ratios:
Our goal is to gain a better understanding of TVTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.47. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.99.
On December 05, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $10.
On November 20, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $7.Citigroup initiated its Neutral rating on November 20, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 01 ’24 when Dube Eric M sold 19,122 shares for $8.70 per share. The transaction valued at 166,435 led to the insider holds 350,600 shares of the business.
REED ELIZABETH E sold 4,764 shares of TVTX for $41,495 on Feb 01 ’24. The SVP, GC & CORPORATE SECRETARY now owns 76,270 shares after completing the transaction at $8.71 per share. On Feb 01 ’24, another insider, ROTE WILLIAM E., who serves as the SENIOR VICE PRESIDENT, R&D of the company, sold 4,764 shares for $8.71 each. As a result, the insider received 41,495 and left with 80,720 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 530.48M and an Enterprise Value of 368.41M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 2.61. Its current Enterprise Value per Revenue stands at 2.54 whereas that against EBITDA is -1.13.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $22.75, while it has fallen to a 52-week low of $5.25. The 50-Day Moving Average of the stock is 8.02, while the 200-Day Moving Average is calculated to be 10.08.
Shares Statistics:
The stock has traded on average 1.23M shares per day over the past 3-months and 920.25k shares per day over the last 10 days, according to various share statistics. A total of 75.37M shares are outstanding, with a floating share count of 75.03M. Insiders hold about 1.41% of the company’s shares, while institutions hold 113.82% stake in the company. Shares short for TVTX as of Mar 15, 2024 were 10.07M with a Short Ratio of 8.22, compared to 9.76M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.24% and a Short% of Float of 13.30%.
Earnings Estimates
Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$0.97 for the current quarter, with a high estimate of -$0.55 and a low estimate of -$1.27, while EPS last year was -$1.27. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.63 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$2.43 and -$4.1 for the fiscal current year, implying an average EPS of -$3.18. EPS for the following year is -$1.75, with 11 analysts recommending between $0.16 and -$2.46.
Revenue Estimates
13 analysts predict $44.37M in revenue for the current quarter. It ranges from a high estimate of $60.85M to a low estimate of $38M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $56.99M, an estimated decrease of -22.10% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $51.75M, a decrease of -13.30% over than the figure of -$22.10% in the same quarter last year. There is a high estimate of $66M for the next quarter, whereas the lowest estimate is $42M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $267M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $216.11M. In the same quarter a year ago, actual revenue was $145.24M, up 48.80% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $309.08M in the next fiscal year. The high estimate is $513.31M and the low estimate is $218M. The average revenue growth estimate for next year is up 43.00% from the average revenue estimate for this year.
